Indications for RENAGEL TABLETS:

Control of serum phosphorus in patients with chronic kidney disease on dialysis.


Swallow whole with meals. Patients not taking a phosphate binder: serum phosphorus >5.5 to <7.5mg/dL: 800mg 3 times daily; ≥7.5–<9mg/dL: 1.6g 3 times daily; ≥9mg/dL: 1.6g 3 times daily. Titrate by 1 tab per meal at 2-week intervals to keep serum phosphorus ≤5.5mg/dL. Switching from calcium acetate to sevelamer: see full labeling.


Not established.


Bowel obstruction.


Dysphagia. Swallowing disorders; consider susp form. Severe GI motility disorders. Major GI tract surgery. Monitor serum bicarbonate, chloride. Monitor for reduced Vitamins D, E, K and folic acid levels; consider supplementation (esp. in pregnant and nursing mothers). Elderly. Pregnancy.

Pharmacologic Class:

Phosphate binder.


Concomitant with drugs that have a narrow therapeutic index; monitor. Consider separation of administration with cyclosporine, tacrolimus, or levothyroxine. Separate dosing of ciprofloxacin by ≥2hrs before or 6hrs after sevelamer; mycophenolate mofetil by ≥2hrs before sevelamer. May decrease serum levels of fat soluble vitamins and folic acid.

Adverse Reactions:

Vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, constipation; rare: bowel obstruction, perforation.

How Supplied:

Tabs 800mg—180